eli lilly and company

Eli Lilly's SWOT analysis: stock poised for growth amid challenges

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity treatments,

Seeking Alpha · 10h

Eli Lilly Stock's Correction Brings Opportunity

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The Motley Fool on MSN · 4d

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

24/7 Wall St · 12d

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Zacks.com on MSN · 1d

Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same time,

13hon MSN

Is Eli Lilly and Company (LLY) the Best Stock to Buy in 2025 for Beginners?

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best ...

Ibj.com13h

Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

BizTimes2d

Eli Lilly’s planned $3 billion investment in Pleasant Prairie called a ‘watershed moment’ for local economy

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

Seeking Alpha2d

LLY Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Hosted on MSN1d

What Does the Future Hold for Eli Lilly?

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics